2025 Q4 -tulosraportti
Vain PDF
102 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenTHIS STOCK SHOULD REALLY NOT BE AVAILABLE TO YOU. 🔓🧬 Think about it for a second. The hottest technologies in the world are never reached by ordinary people. When something is truly groundbreaking, it gets bought up, held private, or locked away behind venture funds and American stock exchanges before you and I even hear about it. 🔒 Look at the circRNA field. Orna? Bought by Lilly. Capstan? AbbVie. Orbital? BMS. One after another — swallowed by giants while they were still early. Gone from the market before you got the chance. 💸 And those who do exactly what Circio does — vector-based circRNA, produced directly inside the body? From what I find, there is no known direct competitor. A niche of its own. Circio calls itself the pioneer in it. 🔵 So here we sit with a paradox: A world-class technology, in a niche almost no one else is in, in the hottest field in modern medicine — and it is listed on the Oslo Stock Exchange. Open. For anyone. For you. 🇳🇴 That almost never happens. Usually, the party is over before you get in. Here, the door is still open. 👀 One day it will be closed — either by an acquisition, a license, or because the rest of the world finally wakes up. Right now, you can still walk through it. We know what we own. ♟️🧱🍷
I am also monitoring whether foreign investors are coming in. There isn't much to suggest that anyone has started accumulating significantly yet. I must say that is a bit disappointing. I had hoped that the weeks after Boston would generate some more activity. I believe many are sitting on the fence waiting for the technology to become more mature. And that the risk will decrease somewhat. I am unsure if that will be this year or next year. But both my wallet and the hope for a technology that can help many people make me cross both my fingers and butt hair in the coming months
·4 t sittenThe string of super-positive feedback from many potential applications for Circio's products has been coming in throughout the summer. Based on all this positivity, there's something I don't quite understand. Why isn't BP on the field already at this stage? If all this fantastic stuff we read has any merit, shouldn't BP be more (much more) interested than us shareholders in securing a large or smaller piece of the pie? As I see it, we can compare the stage Circio is at today with a prime plot of land. E.g., the NRK plot at Marienlyst. Everyone in the industry, even before completed rezoning, knew that the final product would be a success. Everyone jumped on the bidding carousel, and the price went through the roof. Up until today, the rezoning has not been confirmed. Within Big Pharma, one would also think that the buying triggers already at this stage would initiate concrete inquiries towards Circio (land owner). I don't know this industry well enough to define the buying triggers for those who need the product, or is BP sitting on the fence because they don't quite trust whether circRNA is the "prime plot"?
BP is not expensive, it's people who have big roles in decision-making. Many meetings, prestige, career, etc.... many considerations to take! It's many billions USD that is being talked about. Erik and co are enjoying themselves now but the "big ones" are fighting for the best platform and their future! Can they afford to wait? Hypothesis that this "big" player is in negotiations with Circio…about something or other?! Do they have a clause? We must wait but I'm sitting comfortably and am otherwise doing well in life!!🕺 Good week. I have faith!🌞😎- ·5 t sittenTekinvestor … «This statement is quite self-confident: “Circio is the global leader in vector-based circRNA expression systems with no known competitors with comparable versatlity and performance.” I guess this is primarily because Circio is the only company where “the expression system” is DNA and not RNA. DNA is much simpler, cheaper and “off-the-shelf” to work with than RNA. And as I have pointed out earlier, precisely the use of DNA is brilliantly ingenious. So yes: Circio is super-sexy. And they know it «:
·5 t sittenJust for speculation. This looks promising in many ways. How much do people think this stock could be worth if the research becomes revolutionary and the lab tests go the right way - all the way and there is an acquisition? Thinking then best case scenario.
So theoretically, there are no limits to what Circio can be worth. A lot of medicine in the world can potentially benefit from circVec; Vaccines, Gene therapy, Obesity medicine, cancer treatment etc. Just consider that globally annually, approximately 800 billion dollars are spent on cancer treatments. What do you think is spent on vaccines and obesity medicine?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
102 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenTHIS STOCK SHOULD REALLY NOT BE AVAILABLE TO YOU. 🔓🧬 Think about it for a second. The hottest technologies in the world are never reached by ordinary people. When something is truly groundbreaking, it gets bought up, held private, or locked away behind venture funds and American stock exchanges before you and I even hear about it. 🔒 Look at the circRNA field. Orna? Bought by Lilly. Capstan? AbbVie. Orbital? BMS. One after another — swallowed by giants while they were still early. Gone from the market before you got the chance. 💸 And those who do exactly what Circio does — vector-based circRNA, produced directly inside the body? From what I find, there is no known direct competitor. A niche of its own. Circio calls itself the pioneer in it. 🔵 So here we sit with a paradox: A world-class technology, in a niche almost no one else is in, in the hottest field in modern medicine — and it is listed on the Oslo Stock Exchange. Open. For anyone. For you. 🇳🇴 That almost never happens. Usually, the party is over before you get in. Here, the door is still open. 👀 One day it will be closed — either by an acquisition, a license, or because the rest of the world finally wakes up. Right now, you can still walk through it. We know what we own. ♟️🧱🍷I am also monitoring whether foreign investors are coming in. There isn't much to suggest that anyone has started accumulating significantly yet. I must say that is a bit disappointing. I had hoped that the weeks after Boston would generate some more activity. I believe many are sitting on the fence waiting for the technology to become more mature. And that the risk will decrease somewhat. I am unsure if that will be this year or next year. But both my wallet and the hope for a technology that can help many people make me cross both my fingers and butt hair in the coming months
- ·4 t sittenThe string of super-positive feedback from many potential applications for Circio's products has been coming in throughout the summer. Based on all this positivity, there's something I don't quite understand. Why isn't BP on the field already at this stage? If all this fantastic stuff we read has any merit, shouldn't BP be more (much more) interested than us shareholders in securing a large or smaller piece of the pie? As I see it, we can compare the stage Circio is at today with a prime plot of land. E.g., the NRK plot at Marienlyst. Everyone in the industry, even before completed rezoning, knew that the final product would be a success. Everyone jumped on the bidding carousel, and the price went through the roof. Up until today, the rezoning has not been confirmed. Within Big Pharma, one would also think that the buying triggers already at this stage would initiate concrete inquiries towards Circio (land owner). I don't know this industry well enough to define the buying triggers for those who need the product, or is BP sitting on the fence because they don't quite trust whether circRNA is the "prime plot"?BP is not expensive, it's people who have big roles in decision-making. Many meetings, prestige, career, etc.... many considerations to take! It's many billions USD that is being talked about. Erik and co are enjoying themselves now but the "big ones" are fighting for the best platform and their future! Can they afford to wait? Hypothesis that this "big" player is in negotiations with Circio…about something or other?! Do they have a clause? We must wait but I'm sitting comfortably and am otherwise doing well in life!!🕺 Good week. I have faith!🌞😎
- ·5 t sittenTekinvestor … «This statement is quite self-confident: “Circio is the global leader in vector-based circRNA expression systems with no known competitors with comparable versatlity and performance.” I guess this is primarily because Circio is the only company where “the expression system” is DNA and not RNA. DNA is much simpler, cheaper and “off-the-shelf” to work with than RNA. And as I have pointed out earlier, precisely the use of DNA is brilliantly ingenious. So yes: Circio is super-sexy. And they know it «:
- ·5 t sittenJust for speculation. This looks promising in many ways. How much do people think this stock could be worth if the research becomes revolutionary and the lab tests go the right way - all the way and there is an acquisition? Thinking then best case scenario.So theoretically, there are no limits to what Circio can be worth. A lot of medicine in the world can potentially benefit from circVec; Vaccines, Gene therapy, Obesity medicine, cancer treatment etc. Just consider that globally annually, approximately 800 billion dollars are spent on cancer treatments. What do you think is spent on vaccines and obesity medicine?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
102 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenTHIS STOCK SHOULD REALLY NOT BE AVAILABLE TO YOU. 🔓🧬 Think about it for a second. The hottest technologies in the world are never reached by ordinary people. When something is truly groundbreaking, it gets bought up, held private, or locked away behind venture funds and American stock exchanges before you and I even hear about it. 🔒 Look at the circRNA field. Orna? Bought by Lilly. Capstan? AbbVie. Orbital? BMS. One after another — swallowed by giants while they were still early. Gone from the market before you got the chance. 💸 And those who do exactly what Circio does — vector-based circRNA, produced directly inside the body? From what I find, there is no known direct competitor. A niche of its own. Circio calls itself the pioneer in it. 🔵 So here we sit with a paradox: A world-class technology, in a niche almost no one else is in, in the hottest field in modern medicine — and it is listed on the Oslo Stock Exchange. Open. For anyone. For you. 🇳🇴 That almost never happens. Usually, the party is over before you get in. Here, the door is still open. 👀 One day it will be closed — either by an acquisition, a license, or because the rest of the world finally wakes up. Right now, you can still walk through it. We know what we own. ♟️🧱🍷I am also monitoring whether foreign investors are coming in. There isn't much to suggest that anyone has started accumulating significantly yet. I must say that is a bit disappointing. I had hoped that the weeks after Boston would generate some more activity. I believe many are sitting on the fence waiting for the technology to become more mature. And that the risk will decrease somewhat. I am unsure if that will be this year or next year. But both my wallet and the hope for a technology that can help many people make me cross both my fingers and butt hair in the coming months
- ·4 t sittenThe string of super-positive feedback from many potential applications for Circio's products has been coming in throughout the summer. Based on all this positivity, there's something I don't quite understand. Why isn't BP on the field already at this stage? If all this fantastic stuff we read has any merit, shouldn't BP be more (much more) interested than us shareholders in securing a large or smaller piece of the pie? As I see it, we can compare the stage Circio is at today with a prime plot of land. E.g., the NRK plot at Marienlyst. Everyone in the industry, even before completed rezoning, knew that the final product would be a success. Everyone jumped on the bidding carousel, and the price went through the roof. Up until today, the rezoning has not been confirmed. Within Big Pharma, one would also think that the buying triggers already at this stage would initiate concrete inquiries towards Circio (land owner). I don't know this industry well enough to define the buying triggers for those who need the product, or is BP sitting on the fence because they don't quite trust whether circRNA is the "prime plot"?BP is not expensive, it's people who have big roles in decision-making. Many meetings, prestige, career, etc.... many considerations to take! It's many billions USD that is being talked about. Erik and co are enjoying themselves now but the "big ones" are fighting for the best platform and their future! Can they afford to wait? Hypothesis that this "big" player is in negotiations with Circio…about something or other?! Do they have a clause? We must wait but I'm sitting comfortably and am otherwise doing well in life!!🕺 Good week. I have faith!🌞😎
- ·5 t sittenTekinvestor … «This statement is quite self-confident: “Circio is the global leader in vector-based circRNA expression systems with no known competitors with comparable versatlity and performance.” I guess this is primarily because Circio is the only company where “the expression system” is DNA and not RNA. DNA is much simpler, cheaper and “off-the-shelf” to work with than RNA. And as I have pointed out earlier, precisely the use of DNA is brilliantly ingenious. So yes: Circio is super-sexy. And they know it «:
- ·5 t sittenJust for speculation. This looks promising in many ways. How much do people think this stock could be worth if the research becomes revolutionary and the lab tests go the right way - all the way and there is an acquisition? Thinking then best case scenario.So theoretically, there are no limits to what Circio can be worth. A lot of medicine in the world can potentially benefit from circVec; Vaccines, Gene therapy, Obesity medicine, cancer treatment etc. Just consider that globally annually, approximately 800 billion dollars are spent on cancer treatments. What do you think is spent on vaccines and obesity medicine?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt